The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The basal subtype to predict clinical benefit from neoadjuvant chemotherapy: Final results from a phase II clinical trial of DDMVAC plus bevacizumab.
 
Arlene O. Siefker-Radtke
Consulting or Advisory Role - Celgene; Dendreon; Janssen; Merck; NCCN; Threshold Pharmaceuticals
Research Funding - Genentech; Millennium/Prometrika
 
Woonyoung Choi
Patents, Royalties, Other Intellectual Property - MD Anderson Cancer Center
 
Sima P. Porten
No Relationships to Disclose
 
Yu Shen
No Relationships to Disclose
 
Ashish M. Kamat
Honoraria - Abbott Laboratories; Photocure; Sanofi
Consulting or Advisory Role - Archimedes; Taris
Research Funding - Celgene; Endo Pharmaceuticals; FKD Therapies
 
Surena F. Matin
No Relationships to Disclose
 
Colin P. N. Dinney
Honoraria - Merck Sharp & Dohme
Consulting or Advisory Role - FKD Therapies; Merck Sharp & Dohme
Research Funding - FKD Therapies
Travel, Accommodations, Expenses - Merck Sharp & Dohme
 
Bogdan Czerniak
No Relationships to Disclose
 
David James McConkey
Stock and Other Ownership Interests - ApoCell
Honoraria - Millennium/Prometrika; Takeda
Research Funding - AstraZeneca
Patents, Royalties, Other Intellectual Property - MD Anderson Cancer Center
Travel, Accommodations, Expenses - Millennium/Prometrika; Takeda